Navigation Links
Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
Date:3/12/2009

ucts and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
2. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
3. Wyeth Declares Preferred Stock Dividend
4. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
5. Wyeth Wins Philadelphia Diet Drug Trial Involving Claim of PPH
6. Wyeth Announces Increase in Common Stock Dividend
7. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
8. Wyeth Sets Webcast And Conference Call for 2008 Third Quarter Earnings
9. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
10. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
11. Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... reached a definitive agreement with Novartis Pharma AG to ... currently in Phase 3 development.  This agreement is conditional on ... PLC (GSK) on April 22, 2014, which are expected to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... PRINCETON, N.J., Dec. 8 BioWa, Inc., announced today ... its POTELLIGENT(R) Technology for,use in developing and commercializing select ... "GSK is recognized ... drug,discovery," said Dr. Masamichi Koike, BioWa President and CEO. ...
... Dec. 7 Data on Cytopia,s (ASX: CYT) JAK2 inhibitor CYT387 will ... Francisco. The talk will be presented by Dr Thomas Bumm ... CYT387 in an in- vivo model of myeloproliferative disorders. , ... Effects of CYT387, a Potent Novel JAK2 Inhibitor on ...
... Dynamic Alert,Limited (OTC Bulletin Board: DYMC) is pleased ... markets for its pharmaceutical product line-up. The,modalities will ... rapid onset,through oromucosal absorption, topical applications, such as ... Some products will have,specific uses, while others may ...
Cached Biology Technology:BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 2Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products 3
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... Institute have identified a molecular interaction that triggers a ... attacking this target with selective drugs might improve treatment. ... a team led by Qunyan Yu, MD, and Peter ... of a certain mutated oncogene and the newly described ...
... all-important channels that control the flow of information in and ... for the split to come when a cell divides. Now, ... Biological Studies watched as new funnel-like pore structures formed from ... This discovery adds to the picture of how a cell ...
... a gene previously linked to impulsive violence appears ... memory and thinking in humans, researchers at the ... Mental Health (NIMH) have found. Brain scans revealed ... to have relatively smaller emotion-related brain structures, a ...
Cached Biology News:New cellular flaw found in some virulent breast cancers 2New cellular flaw found in some virulent breast cancers 3Researchers solve mystery of how nuclear pores duplicate before cell division 2Aggression-related gene weakens brain's impulse control circuits 2Aggression-related gene weakens brain's impulse control circuits 3
... of Japan, also named Sendai virus) Envelope ... of molecules by means of membrane fusion. ... Protein, Oligo, cDNA, Antibodies, Vector, and Biomolecule ... EX has a high fusing capability in ...
... S. pombe Whole Genome ChIP-on-chip Microarray ... of yeast (S. pombe) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... designed for easy transformation of the budding ... successful transformation simply by mixing a plasmid ... yeast cells. No complicated steps, such as ... kit is particularly well suited for high-throughput ...
... The STag Purification Kits enable rapid analytical ... fusion proteins produced from appropriate vectors. Sufficient ... to 1 mg target protein under native ... with S-protein Agarose, which specifically retains STag ...
Biology Products: